40 results about "Renal damage" patented technology

The invention discloses a preparation method of an astragalus extract with a uric acid reducing effect, and belongs to the technical field of biological medicines. The method comprises the following steps: concentrating an ethanol extract of radix astragali, extracting by using n-butyl alcohol, ethyl acetate and petroleum ether respectively, and concentrating an extract to obtain n-butyl alcohol, ethyl acetate and petroleum ether extraction parts and residual parts respectively, so as to obtain an n-butyl alcohol extract, namely the radix astragali extract for reducing uric acid. Efficacy experiments show that the normal butanol extraction part of the ethanol extract of the astragalus membranaceus can obviously reduce the serum uric acid level (SUA) of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) and effectively improve kidney injury caused by the hyperuricemia. The uric acid reducing effect of the radix astragali n-butyl alcohol extract is close to that of a clinical drug allopurinol, and the radix astragali n-butyl alcohol extract has wide development and application prospects in the aspect of relieving hyperuricemia.

The present invention relates to a composition for preventing, alleviating or treating metabolic diseases, the composition comprising a rosuvastatin and ursodeoxycholic acid conjugate or a pharmaceutically acceptable salt thereof, in which the statin conjugates to an ursodeoxycholic acid transporter and has the effects of function inhibition, cholesterol level reduction, antilipid toxicity, body weight reduction, blood lipid reduction, fatty liver alleviation, inflammation alleviation, and kidney damage alleviation. The composition, in the form of a single formulation, has the characteristics of maintaining the therapeutic effects of rosuvastatin and ursodeoxycholic acid while reducing the side effects of existing statins, and thus can be widely used as a substitute for complex formulations in the treatment of metabolic diseases.

The application discloses a lactobacillus johnsonii OD-5 and application and products thereof, and belongs to the technical field of microorganisms. A technical problem to be solved by the application is to provide a lactobacillus johnsonii capable of treating kidney stones. A technical solution is a lactobacillus johnsonii OD-5 with a preservation number of CGMCC No. 38426. The lactobacillus johnsonii can reduce urine oxalic acid and regulate urine calcium, effectively correct abnormal urine biochemical conditions promoting stone formation, reduce related kidney function damage, and inhibit formation and deposition of calcium oxalate crystals in the kidney at a histopathological level, thereby significantly reducing the stone incidence. The application provides a solid theoretical basis for development of products taking the lactobacillus johnsonii OD-5 as a core component and used for preventing kidney stones and improving stone kidney damage.

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

The application discloses application of Dingxuan Granules in preparation of medicines for treating early kidney damage caused by hypertension of the type of yin deficiency and yang hyperactivity, and the Dingxuan Granules are prepared from radix rehmanniae, lycium barbarum, gastrodia, uncaria, wine salvia miltiorrhiza, alisma, motherwort and achyranthes bidentata. The Dingxuan Granules have the effects of tonifying liver and kidney, calming liver wind and promoting water and descending qi, and are suitable for people with early kidney damage caused by hypertension.

The present invention relates to dihydroquinazolinone compound, a preparation method therefor, and a use thereof. The dihydroquinazolinone compound has an excellent inhibitory effect on GLUT9, can effectively inhibit GLUT9 activity so as to promote uric acid excretion, thereby achieving a uric acid lowering effect, and can be used for treating diseases related to GLUT9 activity or expression. The dihydroquinazolinone compound or a pharmaceutically acceptable salt thereof has no obvious toxicity to organs, can significantly reduce kidney damage caused by hyperuricemia, and alleviates gout symptoms.

Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.

The invention belongs to the technical field of medicines, and particularly relates to application of a small molecule regulator to improvement of AKI treatment by promoting EPC cell differentiation. In order to develop a new AKI treatment scheme, the research finds that the Orticumab can promote EPC cell differentiation (not only can enhance cell viability and up-regulate an anti-inflammatory factor IL-10, but also can down-regulate proinflammatory factors TNF-alpha, IL-1beta and IL-6), so that kidney tissue damage after mouse renal ischemia reperfusion is effectively relieved, renal function deterioration is relieved, and inflammatory response is inhibited. The application shows that the Orticumab can improve the renal ischemia reperfusion injury by promoting the differentiation of EPC cells so as to play a role in protecting the renal I / R injury, and the discovery provides a new therapeutic scheme for improving AKI.

This invention relates to the application of Y27632 in the preparation of drugs that promote the repair and / or regeneration of kidney injury, and pertains to the field of pharmaceutical technology. The application of Y27632 in the preparation of drugs that promote the repair and / or regeneration of kidney injury. This invention demonstrates for the first time the significant effect of Y27632 in promoting the repair and regeneration of acute kidney injury in mice, providing strong experimental evidence for the development of novel drugs for the repair and / or regeneration of kidney injury. This invention provides a new and effective means of treating kidney injury, such as acute kidney injury, by using the ROCK signaling pathway inhibitor Y27632. Experiments of this invention confirm that Y27632 can effectively promote the repair and regeneration of kidney injury by inhibiting the ROCK signaling pathway, upregulating SOX-9 expression, activating the endogenous repair mechanism of the kidney, reducing the expression of damage markers, alleviating kidney pathological damage, relieving renal fibrosis, and salvaging kidney function. This has significant clinical application value and broad market prospects.

The invention discloses an application and a preparation method of a marine fish protein peptide with effects of reducing uric acid and protecting kidneys. The marine fish protein peptide VK with uric acid reduction and kidney protection activity is prepared, and the marine fish protein peptide VK can remarkably reduce the blood uric acid level in the body and improve pathological injury of the kidney. Furthermore, the preparation process is further optimized, and the content of the dipeptide VK in the zymolyte is increased. The preparation method provided by the invention is simple in process, realizes enzymolysis controlled release of the target polypeptide, and can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury.

The invention relates to the technical field of biological medicine, and particularly discloses a platelet membrane-coated mitochondrial compound and a preparation method and application thereof, and the platelet membrane-coated mitochondrial compound comprises mitochondria extracted from mammalian tissues and a platelet membrane coating the outer layer of the mitochondria. According to the present invention, the high kidney injury targeting enrichment rate is achieved through the PMITO compound constructed by coating the mitochondria with the platelet membrane, the healthy mitochondria is accurately delivered to the focus, and the energy crisis and the cell apoptosis are directly reversed; meanwhile, the biomimetic membrane structure can actively adsorb key inflammatory factors such as TNF-alpha and IL-1beta to synergistically realize dual mechanisms of energy repair and inflammation regulation, so that renal function indexes are remarkably improved in an animal model, and tissue pathological damage is relieved; finally, a new strategy for treating the renal ischemia-reperfusion injury, which is high in targeting property, clear in curative effect and good in biological safety, is formed.

The invention provides application of inhibiting expression of split protein in uranium-induced renal injury repair and treatment targets, the split protein comprises Drp1 and Fis1, and by inhibiting expression of the split protein Drp1 and Fis1, the concentration of glutathione and SOD enzyme activity after uranium-induced renal injury are improved, the concentration of malondialdehyde after uranium-induced renal injury is reduced, and the uranium-induced renal injury repair effect is improved. And the oxidative stress reaction caused by uranium can be recovered.

The present application belongs to the technical field of bioactive peptides, functional food and biological medicine, and particularly relates to a marine fish-derived xanthine oxidase inhibiting heptapeptide NPLVTPP and its application in reducing uric acid. The present application discloses a marine fish-derived heptapeptide NPLVTPP with xanthine oxidase inhibiting activity, and the amino acid sequence of the heptapeptide is Asn-Pro-Leu-Val-Thr-Pro-Pro. The heptapeptide can be prepared by solid-phase chemical synthesis or marine fish protein enzymatic separation and purification, can significantly inhibit xanthine oxidase activity, reduce uric acid generation, can effectively reduce serum uric acid level in a hyperuricemia animal model, and can improve high uric acid related kidney function damage. The present application also protects the application of the heptapeptide in preparing xanthine oxidase inhibitors, uric acid reducing products, products for preventing or improving hyperuricemia and kidney damage, and a medicine, food or nutritional composition containing the heptapeptide. The polypeptide sequence of the present application is clear, the target is clear, the in vivo and in vitro efficacy is clear, the source is safe, and the polypeptide can be used in the fields of functional food and biological medicine.

An imidazole dipeptide composition having renal protective efficacy and its application. The imidazole dipeptide composition having renal protective efficacy comprises anserine and carnosine, wherein, when the total weight of anserine and carnosine is 100%, the content of anserine is 10% to 99% and the content of carnosine is 1% to 90%. In a mouse test, mice with hyperuric kidney damage showed significantly less kidney damage compared to the control group after continuously consuming the imidazole dipeptide composition for a certain period, and the imidazole dipeptide composition was proven to have an excellent renal protective effect.

The application discloses application of a preparation for inhibiting IL4I1 expression in preparation of a medicine for treating renal fibrosis, and belongs to the technical field of biological medicine.The application finds through in-vivo and in-vitro experiments that IL4I1 is closely related to kidney injury and renal fibrosis, and is a potential target for treating kidney injury and renal fibrosis.IL4I1 inhibitors are substances capable of inhibiting IL4I1 enzyme activity, and the in-vivo and in-vitro experimental results show that, for example, extract of plantago, salted plantago extract, verbascoside, isoverbascoside and akebone phenylethanoid glycoside B are all beneficial to relieving renal fibrosis.The application provides theoretical support for developing a medicine for treating renal function impairment and treating and / or relieving renal fibrosis disease by inhibiting IL4I1.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

The present application discloses a human faecal blautia strain capable of colonizing in an anaerobic environment of the intestinal tract and an application thereof, and relates to the technical field of microorganisms.The present application provides a strain with a uric acid degradation function, the human faecal blautia strain GH001, which has the effects of reducing uric acid level, preventing and treating hyperuricemia and gout, and the human faecal blautia strain GH001 also has the effect of relieving kidney damage to a certain extent.The present application provides a new probiotic or drug material for the treatment of hyperuricemia and related diseases.In addition, the strain has no obvious influence on the indicators of the sample body, which proves that the strain has the characteristics of high safety and can be widely applied in the medical field.

Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

Provided are methods of treating Fabry disease in a patient having severe renal impairment. A method for the treatment of Fabry disease in a patient having severe renal impairment, including administering to the patient about 50 mg to about 200 mg free base equivalent (FBE) of migalastat or salt thereof at a frequency of less than once every week. A method for the treatment of Fabry disease in a patient having severe renal impairment, including administering to the patient about 50 mg to about 100 mg free base equivalent of migalastat or salt thereof at a frequency of between about once every three days and about once every two weeks.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1. Monoclonal anti-NBL1 antibodies are also provided.

The application provides application of LBP in preparation of drugs for preventing or treating kidney injury. Research results show that LBP intervention can significantly improve cisplatin-induced kidney injury and presents a certain dose dependence; specifically, the serum Cre and BUN levels are significantly reduced, thereby improving kidney function, and the pathological structure damage of kidney tissue is obviously reduced. Further research shows that LBP can enhance the antioxidant capacity of the body and inhibit the inflammatory response by regulating the Nrf2 / NF-kappa B signal pathway, and promote kidney cell survival and regulate metabolism by regulating the PI3K / Akt / mTOR signal pathway, thereby playing a kidney protection role. The application provides a theoretical basis for application of natural active polysaccharides in prevention and treatment of kidney injury.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of charred astragalus in the preparation of drugs that inhibit aristolochic acid-induced kidney damage. Animal experiments have shown that charred astragalus inhibits aristolochic acid-induced kidney damage through anti-oxidative stress, anti-inflammation, and inhibition of apoptosis pathways.

The invention belongs to the technical field of medicines, and finds that aporphine alkaloids, especially magnoline and nuciferine, can reduce the BUN level and SCr level of a cisplatin-induced acute kidney injury model mouse through a large number of experimental screening, can obviously relieve cisplatin-induced kidney function impairment, and can be used for preparing medicines for treating acute kidney injury. The compound can be used as a medicine for reducing adverse reaction of renal function impairment caused by cis-platinum.

The application belongs to the field of biomedicine, and particularly relates to application of a PCSK9 inhibitor in preparation of a drug for treating hypothyroidism with hyperlipidemia. In view of the problem that statins are prone to cause early liver and kidney function damage in the process of reducing lipids in the population with hypothyroidism and hyperlipidemia, the application proves through a mouse model experiment that the PCSK9 inhibitor (alirocumab) has a better effect on reducing LDL-C and VLDL-C in the mouse model, has no influence on thyroid function, can reduce liver and kidney damage, relieve inflammation and oxidative stress, and remodel lipid spectrum. For the population with hypothyroidism and hyperlipidemia, the PCSK9 inhibitor (alirocumab) has both efficacy and safety compared with statins, and has a good clinical application prospect.

The present disclosure belongs to the technical field of biological medicine, and particularly relates to the application of finerenone in the preparation of a drug for treating hypertensive renal injury. The present disclosure provides the application of finerenone in the preparation of a drug for preventing and / or treating hypertensive renal injury, specifically, by using a deoxycorticosterone acetate-salt-induced hypertensive mouse model and a primary mouse renal tubular epithelial cell-bone marrow-derived macrophage co-culture model, it is first revealed that aldosterone and salt corticosteroid receptor signals mediate cell-to-cell communication by promoting PANX1-dependent ATP release in renal tubular epithelial cells, and then activate macrophage P2X7, activate NLRP3-mediated macrophage pyroptosis, and aggravate the molecular mechanism of aldosterone-driven renal inflammation and fibrosis. The present disclosure also provides the application of a substance targeting a PANX1 / extracellular ATP / P2X7 signal axis in the preparation of a drug for preventing and / or treating hypertensive renal injury.

The invention belongs to the technical field of biology, and particularly relates to application of lupeol to preparation of a medicine for preventing or treating renal injury caused by cis-platinum. The invention discovers that the natural compound lupeol has a potential protection effect on the renal injury caused by the cis-platinum for the first time, and in-vivo and in-vitro models prove that the lupeol remarkably relieves renal dysfunction, tissue pathological injury and rising of renal injury markers caused by the cis-platinum, inhibits cell apoptosis and promotes proliferation of renal tubular cells. A transcriptome sequencing result shows that lupeol enhances cell survival and proliferation by activating a PI3K / Akt signal channel, regulates an Nrf2 channel to resist oxidative stress, inhibits nuclear translocation of NF [kappa] B, reduces pro-inflammatory cytokines and inhibits inflammatory response. Results show that lupeol may become a choice for relieving renal toxicity of cis-platinum.